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Abstract
Objective: Being born preterm is related to adverse health effects later in life. We studied whether preterm birth
predicts the risk of migraine.
Methods: In this nationwide register study, we linked data from six administrative registers for all 235,624 children live-
born in Finland (January 1987 to September 1990) and recorded in the Finnish Medical Birth Register. n¼ 228,610
(97.0%) had adequate data and were included. Migraine served as primary outcome variable and was stringently defined
as a diagnosis from specialised health care and/or 2 reimbursed purchases of triptans. We applied sex- and birth year-
stratified Cox proportional hazard regression models to compute hazard ratios and confidence intervals (95% confi-
dence intervals) for the association between preterm categories and migraine. The cohort was followed up until an
average age of 25.1 years (range: 23.3–27.0).
Results: Among individuals born extremely preterm (23–27 completed weeks of gestation), the adjusted hazard
ratios for migraine was 0.55 (0.25–1.24) when compared with the full-term reference group (39–41 weeks). The
corresponding adjusted hazard ratios and 95% confidence intervals for the other preterm categories were: Very pre-
term (28–31 weeks); 0.95 (0.68–1.31), moderately preterm (32–33 weeks); 0.96 (0.73–1.27), late preterm (34–36
weeks); 1.01 (0.91–1.11), early term (37–38 weeks); 0.98 (0.93–1.03), and post term (42 weeks); 0.98 (0.89–1.08).
Migraine was predicted by parental migraine, lower socioeconomic position, maternal hypertensive disorder and mater-
nal smoking during pregnancy.
Conclusion: We found no evidence for a higher risk of migraine among individuals born preterm.
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One in ten children worldwide is born preterm, before
37 completed weeks of gestation (1). Together with the
increased survival rates among preterm infants, this
translates into a substantial share of preterm individu-
als within the adult population. Preterm birth confers
an increased risk of neurocognitive impairment (2),
mental health problems (3), elevated blood pressure
and insulin resistance (4,5) and, at least in populations
born from the 1970s onwards, ischemic heart disease
and stroke (6–9).
During the past decades there has been a surge in
studies elucidating the effects of early life events on
adult health. Still, studies on migraine in individuals
born preterm are sparse, and little is known about
the possible effects of prematurity on the development
of migraine. Babies born preterm are deprived of the
last weeks or months of intrauterine life, a period of
rapid development of the vulnerable foetal brain.
Additionally, they often face immaturity-related ill-
nesses and complications postnatally. Whether these
neurodevelopmental risk factors put them at risk for
migraine later in life is unknown.
Migraine is linked with risk of stroke and cardiovas-
cular disease (10), gestational hypertension (11), psy-
chiatric comorbidity (12), low socioeconomic position
(13), and adverse pregnancy-related outcomes (11,14) –
factors that have all been linked with prematurity as
well (3,6,7,15,16). Given that migraine and prematurity
share a number of associated conditions and knowing
that prematurity affects numerous aspects of neurolog-
ical development (17), we set out to study whether pre-
term birth, across the entire gestational age range, is
associated with migraine in children or young adults.
Methods
Data collection
We conducted a population-based register linkage
study to investigate the occurrence of migraine across
different gestational age groups. We utilised data from
multiple national administrative registers and linked
these data together, using an encrypted form of the
unique personal identifier that is assigned to all resi-
dents in Finland and remains the same throughout life.
The six nationwide registers were: i) the Finnish
Medical Birth Register (MBR), ii) the Central
Population Register (CPR), iii) the Education
Register maintained by Statistics Finland, iv) the
Register of Congenital Malformations, v) the Finnish
Care Register for Health Care, formerly the Hospital
Discharge Register, and vi) the Finnish Prescription
Register. The registers, the validity of the data, and
the study design have been described in detail previous-
ly (18–22).
We utilised the MBR for obtaining data on maternal
background characteristics, pregnancy, delivery and
perinatal outcomes, and for defining the study
cohort. The MBR covers all children born in Finland
from 1987 onwards. Data on death, emigration and
family relationships came from the CPR (updated
through April 2012) and data on educational achieve-
ments from the Education Register (updated through
December 2012). Data on congenital anomalies came
from the Register of Congenital Malformations
(January 2015). The Finnish Care Register for Health
Care contains data on all inpatient hospital discharges
since 1967, and since 1998 also on outpatient hospital
visits in public hospitals, providing us with data on
migraine diagnoses from the specialised health care
(data extracted December 2015). Diagnoses (one main
and two secondary diagnoses) are recorded in the reg-
ister using the International Statistical Classification of
Diseases and Related Health Problems, 8th revision
(ICD-8) during the years 1969–1986, ICD-9 during
1987–1995, and ICD-10 from 1996 onwards (23). We
obtained data on triptan purchases from the Finnish
Prescription Register, maintained by the Finnish Social
Insurance Institution (data extracted December 2013).
In this register, all reimbursed prescription drug pur-
chases are documented since 1994, with 97% coverage
during the first decade (22). The reimbursement system
covers all permanent residents in Finland living in a
non-institutional setting. Thus, reimbursed purchases
of drugs prescribed at public health services, private
practices as well as occupational health are covered.
Triptans were launched in 1991 and entered the
market in Finland in 1992. In 2003, the first triptan
was labelled for use in children 12 years in Finland,
although paediatric off-label use was widespread even
before that (22). Throughout the study period, triptans
were prescriptions drugs in Finland, unapproved for
over-the-counter sale.
Standard protocol approvals, registrations, and
patient consents
The study was approved by the local ethics committee,
The Finnish Ministry of Health and Social Affairs, and
relevant register authorities. Based on EU and Finnish
legislation, individual consents are not required in this
study type based on pseudonymised register data.
Study cohort
The study cohort comprises all live-born children in
Finland between 1 January 1987 and 30 September
1990 who were recorded in the nationwide MBR
678 Cephalalgia 41(6)
(n¼ 235,624, 99.8% of live-born children) (Figure 1).
We excluded participants as described in Figure 1 in
order to keep the exposure as accurate as possible:
Those with missing or doubtful gestational age or
birth weight standard deviation (SD) score, and those
with at least one major congenital anomaly. Six outliers
diagnosed with migraine before the age of 4 years
were omitted, since diagnosing migraine in toddlers
unable to verbally describe symptoms is challenging
and none of them had a migraine diagnosis or triptan
purchase after age 4, indicating probable reporting
error. The final sample included in all analyses consists
of 228,610 participants (97.0% of the original birth
cohort).
Exposure
Gestational age at birth served as exposure variable.
Estimation of gestational age was based on the last
menstrual period and ultrasound estimation (when
available). The gestational age categories were as fol-
lows: Extremely preterm, 23–27 completed weeks
(n¼ 522, 0.2%); very preterm, 28–31 weeks (n¼ 982,
0.4%); moderately preterm, 32–33 weeks (n¼ 1207,
0.5%); late preterm, 34–36 weeks (n¼ 8516, 3.7%);
early term, 37–38 weeks (n¼ 40,570, 17.7%); full
term, 39–41 weeks (n¼ 167,646, 73.3% [reference
group]), and post term, 42 weeks (n¼ 9173, 4.0%)
(24,25).
Outcome variables
Our primary outcome variable was a diagnosis of
migraine from specialised health care and/or at least
two reimbursed purchases of triptans. As secondary
outcomes, we analysed diagnoses of migraine and trip-
tan purchases separately. Specialised health care diag-
noses were extracted from the Finnish Care Register
for Health Care as described above. The ICD codes
extracted are shown in Table 1. As the register does
not cover primary health care, we extracted diagnoses
only from specialised health care. To capture migrai-
neurs diagnosed in the primary care setting, we used
purchases of triptans as a proxy for migraine diagno-
ses. The cut-off was set to 2 reimbursed purchases, in
order to increase specificity and avoid classifying
patients trying triptans on a single occasion as migrai-
neurs. In Finland, reimbursed medication can be
bought for no longer than 3 months at a time.
For the primary outcome, we defined age at event as
the age at first diagnosis, or age at the first purchase (of
2 purchases) of triptans, whichever occurred first.
Statistical analyses
We applied Cox proportional hazard regression models
to compute hazard ratios (HRs) and 95% confidence
intervals (CIs) for the association between gestational
age categories and migraine. The term-born group (39–
41 weeks) served as the reference group. The models
were stratified by birth year and sex of the study
235624 children born in Finland between
January 1, 1987, and September 30,1990,
with a valid personal identification number
(99.8% of all live-born children) 
235554
228616 included in the analyses of
triptan prescriptions
70 (0.03%) excluded due to missing datat in
the Central Population Register
6938 (2.9%) excluded:
437 (0.2%) GA< 23 or > 42+6 weeks
523 (0.2%) with incorrect or missing
birth weight SD score
2949 (1.3%) with ≥1 major congenital
anomalies
3029 (1.3%) lacking information on
gestational age (GA)
6 (<0.001%) outliers excluded:
diagnosis only before 4 years of age






Figure 1. Study cohort.
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participants: Birth year, since it is expected to interfere
with the likelihood of achieving a diagnosis, or triptan
prescription (triptans were launched in 1991 and
increased over the years), and sex because migraine
prevalence and disease course differs between men
and women, and in our cohort, the sex difference in
migraine varied over time (p-value for interaction
between sex and time interval< 0.01) (22,26). The
study participants were followed up until a) receiving
their first diagnosis of migraine, b) until their first reim-
bursed purchase of triptans (in case the participant had
2 purchases during follow-up), c) migration
(n¼ 3208, 1.4%), d) death (n¼ 2395, 1.0%), or end
of follow-up, whichever event occurred first. The
follow-up (rounded to the closest 30 days) ended in
December 2013 for variables including triptan pur-
chases. The mean age at end of follow-up was 25.1
years (range: 23.3–27.0). In secondary analyses, when
analysing diagnoses exclusively, the follow-up extended
until December 2015, the mean age of the participants
being 27.1 years (range: 25.3–29.0)
We adjusted for the following covariates, represent-
ing variables potentially associated with prematurity
and migraine, and chosen on theoretical or statistical
grounds: Birth weight SD score in relation to length of
gestation (using Finnish reference values for intrauter-
ine growth) (27), parental migraine (yes/no, either
parent diagnosed in specialised health care between
1969–2015, not accounting for diagnoses before 1969
or parents possibly lost to follow-up), parental educa-
tional attainment (highest ever of either parent during
follow-up) as a proxy for socioeconomic position,
maternal age and marital status when giving birth
(married, yes/no), birth order (first-born, yes/no),
maternal hypertensive disorder (including preeclampsia
and gestational hypertension) or gestational diabetes.
Maternal smoking during pregnancy (yes/no) was
derived from self-reports at the first antenatal clinic
visit, usually at 9–10 completed gestational weeks. An
adverse neonatal clinical course was operationalised in
terms of an aggregate variable that included asphyxia,
retinopathy of prematurity, or bronchopulmonary dys-
plasia (yes/no), and another aggregate variable called
severe infant morbidity, including diagnoses of severe
neurological, infectious, pulmonary or other neonatal
morbidity. Both aggregate variables were described in
detail previously (18). Additionally, we adjusted for a
diagnosis of developmental delay or intellectual
Table 1. Summary of ICD-8, ICD-9, and ICD-10 codes extracted and included in the analyses.
ICD-8 ICD-9 ICD-10 Diagnosis
– 346 G43 Migraine
– 3461A G43.0 Migraine without aura (common migraine)
– 3460A G43.1 Migraine with aura (classical migraine)
– Including:
– – G43.1 Migraine familial hemiplegic
– – G43.1 Migraine with: Typical aura
– – G43.1 Migraine with: Acute-onset aura
– – G43.1 Migraine with: Prolonged aura
– – G43.1 Migraine aura without headache
– – G43.1 Migraine equivalents
– – G43.1 Migraine basilar
– 3468X G43.2 Status migrainosus
– 3468X G43.3 Complicated migraine
– 3468X G43.8 Other migraine
– – Including:
– – G43.8 Ophthalmoplegic migraine
– – G43.8 Retinal migraine
346.09 3469X G43.9 Migraine, unspecified
– 3468X G44.0a Cluster headache syndromea
– – Including:
– – G44.0 Episodic cluster headache
– – G44.0 Paroxysmal hemicrania
346.01 – G44.0 Hortons disease
– – G44.0 Migraine, episodic, chronic
aG44.0 was included in analyses, since it encompasses the subgroup “migraine, episodic, chronic” and the corresponding
ICD-9 code 3468X, which was also extracted, covers both migraine and cluster headache as well. In line with this
reasoning, ICD-8 code 346.01 was also included.
ICD: International Statistical Classification of Diseases and Related Health Problems.
680 Cephalalgia 41(6)
disability. Table 2 shows the unadjusted associations
between the individual covariates and migraine.
Analyses were run with and without adjustments for
covariates, and finally repeated with singletons only.
Missing values were treated as missing, without data
imputation, meaning that cases with missing values
with respect to any covariate were omitted from the
model (a maximum of 5085 [2.2%] cases were excluded
from the analyses due to missing data). In adjusted
models, covariates were introduced in clusters.
Potential interactions between gestational age and sex
or gestational age and foetal growth (for which small
for gestational age [SGA] served as a proxy) were
examined by introducing the corresponding interaction
terms in the models. SGA was defined as a birth weight
2 SD score for gestational age.
We checked the validity of the proportional hazards
assumption using the Schoenfeld residuals-based test in
R package survival (28) and found no time-dependent
HRs for the gestational age categories and no serious
time dependencies among the covariate effects that
would distort the results obtained from the proportion-
al hazards regression. Otherwise, analyses were con-
ducted with SPSS version 25 (IBM SPSS Statistics;
IBM Corporation). A two-sided p-value of< 0.05 was
considered significant.
Data availability
All relevant analysis results are shared and published in
this article. No individual-level data is openly available:
Only members of the study groups were granted access
to the sensitive data from the relevant registers and
further access rights are subject to permission from
the registers. Interested researchers may apply for
access rights from the registers (18).
Table 2. Independent effects (unadjusted HRs, 95% CI) of specific covariates on later risk of migraine (defined as a diagnosis of
migraine from specialised health care, and/or 2 reimbursed triptan purchases during follow-up).
Covariate HR 95% CI p-value Migraine diagnosis,
yes vs. no n (%)a
Female (versus male) 3.12 2.99 3.26 <0.001 8136 (7.3%) vs. 103,551 (92.7%)
Small for gestational age (birth weight SD score 2)b 1.12 1.00 1.25 0.055 312 (5.2%) vs. 5706 (94.8%)
Being first-born (yes) 0.99 0.95 1.03 0.59 4319 (4.7%) vs. 86,728 (95.3%)
Maternal marital status at birth (married)c 0.97 0.92 1.01 0.13 8536 (4.8%) vs. 170,918 (95.2%)
Maternal smoking during pregnancy (yes)d 1.13 1.07 1.18 <0.001 1798 (5.3%) vs. 32,393 (94.7%)
Gestational diabetes (yes) 0.99 0.88 1.10 0.78 339 (4.7%) vs. 6888 (95.3%)
Maternal hypertensive disorder (yes) 1.10 1.02 1.18 0.018 728 (5.2%) vs. 13,226 (94.8%)
Maternal age at birth (years)e 0.99 0.98 0.99 <0.001 N/Af
Asphyxia, ROP, or BDP (yes)g 0.94 0.86 1.03 0.18 526 (4.5%) vs. 11,288 (95.5%)
Severe infant morbidity (yes)h 0.95 0.78 1.16 0.61 97 (4.3%) vs. 2180 (95.7%)
Parental education, highest level
achieved by either parent
Upper-secondary Reference category
Post-secondaryi 0.95 0.90 0.99 0.020 2538 (4.8%) vs. 50,378 (95.2%)
Lower tertiaryi 0.90 0.85 0.95 <0.001 1331 (4.6%) vs. 27,885 (95.4%)
Upper tertiary or morei 0.79 0.75 0.84 <0.001 1463 (4.0%) vs. 35,049 (96.0%)
Basic or unknowni 1.07 0.99 1.16 0.11 698 (5.3%) vs. 12,421 (94.7%)
Intellectual or developmental disabilityj 0.81 0.61 1.07 0.14 50 (3.8%) vs. 1274 (96.2%)
Parental migrainek 2.07 1.94 2.22 <0.001 930 (9.2%) vs. 9232 (90.8%)
Note: Univariate Cox regression analyses were fit. The cohort (n¼ 228,610) was followed up until December 2013. Cases who emigrated or died
before end of follow-up were censored.
aRefers to the share (n, %) of individuals with versus without a migraine diagnosis within the respective covariate category. Crude values shown: Cases
who emigrated or died before end of follow-up not accounted for.
bReference 27.
Missing values: c1051 (0.5%), d4426 (1.9%), e3 (<0.001%).
fContinuous variable.
gDiagnosed with asphyxia, retinopathy of prematurity (ROP) or bronchopulmonary dysplasia (BPD) before 3 months of age.
hAggregate variable including diagnoses of severe neurological, infectious, pulmonary or other morbidity in the neonatal period (18).
iCompared with reference category (upper-secondary).
jDiagnosed with developmental delay and/or intellectual disability (ICD-10 codes F84, F70-F79; ICD-9 codes 2990, 2998, 2999, 317–319) by December
2012 (49).
kEither biological parent diagnosed with migraine in special health care between 1969–2015 (parents who died or migrated not censored, and those
who received a diagnosis before 1969 not accounted for).
HR: Hazard ratio; CI: confidence interval.
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3 shows background characteristics of the study
cohort by gestational age at birth. As expected, adverse
pregnancy and neonatal characteristics were more
common among those born preterm as opposed to
full term (p-values< 0.05, chi-squared test or t-test).
Indicators of socioeconomic position were less advan-
tageous among preterm individuals (lower parental
educational attainment, fewer mothers married at
birth of study participant, p-values< 0.05, chi-
squared test). Rates of parental migraine were similar
between groups (p-value 0.25, chi-squared test).
Univariate association between covariates and
migraine
Table 2 shows that risk of migraine was higher in
women and among those whose parents suffered
from migraine. Smoking during pregnancy, maternal
hypertensive disorder, and lower parental educational
attainment was associated with higher risk of migraine.
Higher maternal age at birth was linked with lower risk
of migraine in the offspring; however, this association
turned non-significant when analyses were confined to
the interquartile range (ages 24–32 years). The associ-
ation between being SGA and higher risk of migraine
only bordered on significance (HR 1.12, 1.00 to 1.25).
Higher birth weight SD score was associated with
lower risk of migraine among those born full term
only (HR per SD 0.97, 0.95–0.99), but the direction
of the associations in the other gestational age catego-
ries varied and were statistically insignificant.
Univariate analyses showed no associations between
other neonatal morbidity covariates and subsequent
migraine.
Distribution of migraine according to sex and age at
onset
During the follow-up period, the cumulative incidence
of migraine was higher among females than males
(7.3% vs. 2.4% for the main outcome variable,
p< 0.01, chi-squared test) (Table 4). The sex difference
was observable also when analysing secondary out-
comes; that is, migraine diagnoses, migraine with
aura, and triptan purchases separately, being most
marked for triptan purchases (5.1% vs. 1.0%, p-val-
ue< 0.01, chi-squared test) (Table 4). The age at
onset of migraine varied according to sex, as shown
in Figure 2. Females were on average older than
males at onset of migraine and had a unimodal age
at onset-distribution (medians 18.9 vs. 15.4 years for
females and males, p-value< 0.01, Mann-Whitney U-
test). A larger proportion of male migraineurs, com-
pared to female migraineurs, had onset of migraine
below the age of 15 years (46.2% vs 18.5%, p< 0.01).
The age at onset of migraine among males was more
evenly, slightly bimodally, distributed (interquartile
range for males and females: 12.3–20.2 and 16.0–21.7
years). At the end of follow-up, in fully adjusted logis-
tic regression analyses and when we excluded cases who
were lost to follow-up due to death or migration,
female sex conferred a threefold overall risk of
migraine (adjusted odds ratio 3.21, 3.07–3.35).
Gestational age and later migraine
On crude group comparisons (Table 4), migraine
appeared less common among those born at the
lowest gestational age. However, mortality among
these extremely preterm children was high, causing
loss to follow-up at early ages before possibly develop-
ing migraine, and thus the follow-up time needs to be
accounted for in analyses. In order to do so, Cox
regression models, accounting for the follow-up time
for each participant, were fitted. As shown in Table 5
and Figure 3, adjustment for covariates listed in Table
5 revealed no significant association between preterm
birth and subsequent migraine. The results remained
unchanged after an exclusion of multiple births.
There were no significant interactions between gesta-
tional age categories and sex, meaning that the effect of
prematurity on later migraine did not differ between
males and females.
In the final model (Table 5), the following covariates
predicted the primary outcome (i.e. a migraine diagno-
sis and/or 2 triptan purchases) in fully adjusted
models: Parental migraine (aHR 2.07, 95% CI: 1.93–
2.21), maternal smoking during pregnancy (aHR 1.08,
1.02–1.14), maternal hypertensive disorder (aHR 1.13,
1.04–1.22), maternal age at birth (aHR per year 0.99,
0.98–0.99), being first born (aHR 0.94, 0.90–0.98), and
parental educational attainment (aHR 0.83, 0.78–0.89;
for upper tertiary education or more compared to
upper secondary). SGA was not associated with later
migraine.
Discussion
We report on a well-characterised nationwide
population-based study exploring the association
between prematurity across the entire gestational age
range and subsequent risk of migraine up to adulthood.
By linking different national registers and using strin-
gent criteria to define migraine, we were able to identify
10,922 migraineurs among 228,610 study participants
in the birth cohort. We found no evidence for an asso-
ciation between preterm birth and later migraine, trip-
tan purchases or migraine with aura. Parental
migraine, lower socioeconomic position, maternal
Strang-Karlsson et al. 683
Table 4. Distribution of migraine outcome variables at end of follow-up (not accounting for length of follow-up or those lost to
follow-up due to death or migration).
Outcome variable, cases (%)











Number in analyses n¼ 228610d n¼ 228610d n¼ 228616d n¼ 228610d
Extremely preterm, 23–27
(n¼ 522)
6 (1.1) 3 (0.6) 5 (1.0) 0 (0.0)
Very preterm, 28–31
(n¼ 982)
38 (3.9) 26 (2.6) 18 (1.8) 6 (0.6)
Moderately preterm, 32–33
(n¼ 1206)
52 (4.3) 31 (2.6) 38 (3.1) 10 (0.8)
Late preterm, 34–36
(n¼ 8516)
405 (4.8) 269 (3.2) 238 (2.8) 78 (0.9)
Early term, 37–38
(n¼ 40,569)
1895 (4.7) 1252 (3.1) 1183 (2.9) 414 (1.0)
Full term, 39–41
(n¼ 167642)
8095 (4.8) 5257 (3.1) 5125 (3.1) 1765 (1.1)
Post term, 42
(n¼ 9173)
431 (4.7) 285 (3.1) 263 (2.9) 95 (1.0)
Total cohortd 10,922 (4.8) 7123 (3.1) 6870 (3.0) 2368 (1.0)
Men (n¼ 116,923) 2786 (2.4) 2149 (1.8) 1218 (1.0) 619 (0.5)
Women (n¼ 111,687) 8136 (7.3) 4974 (4.5) 5652 (5.1) 1749 (1.6)
Note: Gestational age categories indicate completed weeks.
aFor outcome variables including triptan purchases, follow-up ended in December 2013 (mean age 25.1 years; range: 23.3–27.0).
bFor outcomes on diagnoses only, the follow-up ended in December 2015 (mean age 27.1 years; range: 25.3–29.0).
cParticipants who had ever received a diagnosis of migraine with aura (codes 3460A or G43.1, from the ICD-9 and ICD-10, respectively).
dOutcomes including diagnoses covered n¼ 228,610 participants due to six excluded outliers as described in Figure 1. For outcomes including triptan
purchases only, n¼ 228,616.
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hypertensive disorder and – interestingly – also mater-
nal smoking during pregnancy, predicted higher risk of
migraine in the offspring.
Only a handful of previous studies have explored pre-
and perinatal predictors of headache in general and
migraine in particular. A study on mandibular function
in preterm children and term born controls aged 8–10
years (n¼ 114) showed no group difference in self-
reported headache (29). Also in line with our finding,
another study on maternal-reported headache (migraine
not studied) in 7–11-year-old children failed to report
any effects of gestational age (30). In a retrospective
chart review of a clinical sample of paediatric migrai-
neurs, a history of care in neonatal intensive care units
(NICU) predicted higher levels of pain medication for
migraine and an earlier age at onset of migraine in unad-
justed analyses (31). Prematurity was not separately
investigated. The authors speculated that pain experien-
ces in the NICU might alter later pain experiences
through neuronal plasticity and the resulting central
hyperexcitability. In yet another retrospective chart
review of a clinical sample of 190 paediatric headache
patients, a history of birth asphyxia was more common
in the migraine than the tension-type headache group
(32); however, the study was limited by lack of a non-
headache control group, lack of adjustment for con-
founders, and the definition of asphyxia was partly
based on recall. These findings are not in line with
ours, since in the current study, neonatal morbidity var-
iables did not predict later migraine.
In a questionnaire-based study on 7354 adults aged
19–41 years, foetal growth retardation, operationalised
in terms of a birth weight for gestational age below the
third percentile (corresponding approximately to 2 SD
used in our study) was associated with increased odds
for migraine among males only (33). However, the study
was limited by lack of adjustment for confounders and
the effect of prematurity was not explored, thus it
remains unclear whether the effect of SGA was attrib-
utable to lower gestational age, given that SGA individ-
uals usually are overrepresented in the lower gestational
age groups. In contrast, another study on 11-year-old
children born at term showed no association between
being born SGA and migraine or tension-type headache
(34); however, their criterion for SGA (birth weight for
gestational age< 10th percentile) was less strict and
migraine epidemiology in children differs from that
after puberty (35), possibly partly explaining the discrep-
ancy in results between the two aforementioned studies.
These two studies, together with the lack of a clear-cut
link between SGA and later migraine in our study, sug-
gest there is insufficient evidence to date for a link
between foetal growth retardation and later migraine.
In the current study, maternal smoking during preg-
nancy was associated with an increase in risk of migraine
(HR 1.08) in the offspring, despite adjustment for con-
founders. Although a causal association cannot be veri-
fied in a register-study setting, we consider this finding
interesting and potentially of great importance, since
maternal smoking during pregnancy is an actionable
risk factor and prenatal nicotine exposure has detrimen-
tal effects on the developing foetal brain (36). Our finding
is partly paralleled by a retrospective case-controlled
(n¼ 1440) study based on interviews and standardised
questionnaires, showing that prenatal smoking exposure
increased the risk of chronic daily headache but not epi-
sodic headache among 5–12-year-olds (37). As discussed
by the authors, the study had limited ability to adjust for
socioeconomic position. Our finding is also partly in line
with two longitudinally studied Brazilian birth cohorts
showing higher rates of maternal-reported headache
(migraine not studied) in 7–11-year-olds whose mothers
smoked during pregnancy (30). Another study reported
an association between maternal smoking during preg-
nancy and tension-type headache in 11-year-old children;
yet, no association was seen in adjusted analyses or with
regard to migraine (34). This discrepancy in results in
comparison with our study may, again, be related to
the age range, since the study in question was conducted
in childhood before the peak prevalence of migraine (26).
The sex differences in the present study as well as the
link between lower socioeconomic position and risk of
migraine were as expected based on previous research
(13,15,26,35). Likewise, parental migraine predicted a
higher risk of migraine in the offspring, unsurprisingly,
considering the genetic components of migraine
(38,39). The association between maternal hypertensive
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Figure 3. Risk of migraine according to gestational age category.
Note: Migraine was defined as a migraine diagnosis and/or 2
triptan purchases. The study participants were followed up until
a mean age of 25.1 years (range 23.3–27.0). The term born group
(39–41 completed gestational weeks) served as the reference
group, indicated by the thick horizontal line (HR¼ 1.0). Closed
circles represent unadjusted HRs, and closed square represent
fully adjusted HRs corresponding to Model 2 in Table 5.
Whiskers indicate the 95% CIs.
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in the current study is interesting but needs replication.
Although gestational hypertensive disorders are more
common among migraineurs according to some studies
(11), it is not recognised as an established risk factor for
offspring migraine.
Even though migraine is primarily an episodic condi-
tion, it may progress into chronic migraine, which has
features in common with other chronic pain disorders
(40). Studies have linked migraine to musculoskeletal
symptoms (41) and dysfunctions (42). However, there is
no clear association between gestational age and muscu-
loskeletal pain: One cohort study reported an association
between preterm birth and chronic pain (43), but other
larger studies found no association between preterm birth
and chronic pain in adolescents (44) or widespread mus-
culoskeletal pain in young adults (45). With this back-
ground, the lack of association between gestational age
and migraine in our study may not be unexpected.
The strengths of the study include the sizeable national
birth cohort with high coverage and follow-up into adult-
hood. The whole gestational age range is represented,
which allows for analyses not only across the whole spec-
trum of prematurity, but also across early term and post
term birth categories. The outcome variables were derived
from nationwide registers with proven high validity
(18,22). Linkage between several national registers further
enabled us to adjust for possible confounders and explore
the effect of background variables with negligible num-
bers of missing values. The ethnically homogenous pop-
ulation of Finland at the time when the study participants
were born, with only 0.8% of residents having a foreign
background, presumably reduces possible confounding
by genetic factors (46). On the other hand, it also dimin-
ishes the generalisability of the results to more ethnically
diverse populations, which is a limitation.
As to limitations, our study does not provide data
on the lifetime risk of migraine as the follow-up ended
before 30 years of age, a decade prior to the peak prev-
alence of migraine (47). Nevertheless, at least up until
young adulthood, we detected no association between
gestational age and migraine. Future studies with even
longer follow-up throughout adulthood are needed to
determine whether the lack of association persists. We
had no data on diagnoses from primary health care.
This shortage was in part compensated for by use of
triptan purchases as a proxy, since data on all reim-
bursed triptan purchases prescribed in both specialised
(including all medical specialties) and primary health
outpatient care was available. Paediatric triptan usage
was limited when our study participants were children;
however, it is estimated that 6% of 12- to 17-year-old
migraineurs in Finland were treated with triptans in
2007, at a time when our youngest study participants
were 17 years old (22). Moreover, as we used stringent
criteria for migraine, we may have missed milder cases
not seeking medical attention and thus undiagnosed, or
cases diagnosed in primary health care but not treated
with triptans, given that NSAIDs like ibuprofen and
acetaminophen (paracetamol) are often used as first
line therapy in paediatric migraine. We chose not to
include prescription drugs other than triptans, howev-
er, to avoid including individuals prescribed NSAIDs
for indications other than migraine. Therefore, our
study likely represents an underestimate of the true
prevalence. On the other hand, the stringent criteria
increase the likelihood that cases in our study actually
represent true cases. Supporting the validity of our out-
come variable, a recent Finnish study on migraine in an
occupational health setting ended up with similar
migraine frequencies, despite using somewhat different
methodology (7.4% of women and 2.1% of men, as
compared with 7.3% and 2.4% in our study) (48).
We were unable to account for possible variation in
diagnostic threshold across hospital district. Being a
register study, the diagnoses were not verified from
medical records. Finally, the validity of the parental
migraine covariate was restricted since it was not com-
plemented with triptan purchases, and the follow-up
time for parents was not accounted for.
This large, nationwide register-based study found no
evidence for an association between preterm birth and
subsequent risk of migraine up until young adulthood.
The association between maternal smoking during
pregnancy and subsequent migraine warrants attention
and further study, given that prenatal smoking is an
actionable lifestyle risk factor.
Clinical implications
• Preterm birth, across the entire gestational age range, was not a risk factor for subsequent migraine up
until young adulthood.
• The results are encouraging for preterm individuals and their families, who face several other health
challenges.
• Maternal smoking during pregnancy was associated with an increased risk of migraine in the offspring – an
observation warranting attention and further study, given that prenatal smoking is an actionable lifestyle
risk factor.
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